ID   SK-UT-1B
AC   CVCL_2250
SY   SKUT1B; SK-UT 1B; SKUT-1B; Skut1B
DR   BTO; BTO:0003725
DR   CLO; CLO_0009066
DR   CLDB; cl4359
DR   ATCC; HTB-115
DR   BioSample; SAMN03471096
DR   BioSample; SAMN03472878
DR   cancercelllines; CVCL_2250
DR   ChEMBL-Cells; CHEMBL3307682
DR   ChEMBL-Targets; CHEMBL614678
DR   CLS; 300406
DR   Cosmic; 713478
DR   Cosmic; 871555
DR   Cosmic; 889118
DR   Cosmic; 1007164
DR   Cosmic; 1066227
DR   Cosmic; 1091505
DR   GEO; GSM185152
DR   GEO; GSM185153
DR   GEO; GSM844693
DR   GEO; GSM844694
DR   GEO; GSM1676334
DR   GEO; GSM1701666
DR   IGRhCellID; SKUT1B
DR   IZSLER; BS TCL 210
DR   Progenetix; CVCL_2250
DR   PubChem_Cell_line; CVCL_2250
DR   Wikidata; Q54954651
RX   PubMed=327080;
RX   PubMed=2372783;
RX   PubMed=2766249;
RX   PubMed=3383166;
RX   PubMed=3518877;
RX   PubMed=6935474;
RX   PubMed=9541971;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=28196595;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-ut-1b-human-uterine-leiomyosarcoma-cell-line
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-071.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1096Ter (c.3286C>T); ClinVar=VCV000156475; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg88Gln (c.263G>A); ClinVar=VCV000376049; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323fs*2 (c.968_969insA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Uterus; UBERON=UBERON_0000995.
ST   Source(s): ATCC; CLS; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,13
ST   D16S539: 12,14
ST   D18S51: 11,17
ST   D19S433: 12,13
ST   D21S11: 29,32.2
ST   D2S1338: 19,21
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   D8S1179: 14,15
ST   FGA: 22,23
ST   Penta D: 11,14
ST   Penta E: 17
ST   TH01: 7
ST   TPOX: 5,8 (PubMed=25877200)
ST   TPOX: 8 (ATCC; CLS)
ST   vWA: 16
DI   NCIt; C6340; Uterine corpus leiomyosarcoma
DI   ORDO; Orphanet_213625; Leiomyosarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0533 ! SK-UT-1
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 30
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=2372783; DOI=10.1016/0165-4608(90)90229-4;
RA   Chen T.-R.;
RT   "SK-UT-1B cell line has the diploid karyotype. A reply.";
RL   Cancer Genet. Cytogenet. 48:139-141(1990).
//
RX   PubMed=2766249; DOI=10.1016/0165-4608(89)90119-2;
RA   Pathak S., Dhaliwal M.K.;
RT   "Cytogenetic analysis of a leiomyosarcoma cell line (SK-UT-1B). Normal
RT   diploid or with 21q deletion?";
RL   Cancer Genet. Cytogenet. 41:145-147(1989).
//
RX   PubMed=3383166; DOI=10.1016/0165-4608(88)90052-0;
RA   Chen T.-R.;
RT   "SK-UT-1B, a human tumorigenic diploid cell line.";
RL   Cancer Genet. Cytogenet. 33:77-81(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=9541971;
RA   Poljanskaia G.G., Efremova T.N., Ender N.A.;
RT   "The influence of mycoplasmal contamination of the human uterine
RT   leiomyosarcoma cell line SK-UT-1B on karyotype structure.";
RL   Tsitologiia 40:23-30(1998).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//